Public Meeting on Patient-Focused Drug Development for Huntington’s and Parkinson’s Diseases

On September 22, 2015, FDA is conducting a public meeting on Patient-Focused Drug Development for Huntington’s disease and Parkinson’s disease. FDA is interested in obtaining patients’ perspectives on the impact of patient perspectives on the impact of Huntington’s disease and Parkinson’s disease on daily life and patient views on treatment approaches.

Although these are both neurological diseases, since they are quite distinct, FDA will structure this public meeting into two distinct sessions. The morning session, scheduled from 9 a.m. to 12:30 p.m., will be devoted to Huntington’s disease. The afternoon session, scheduled from 1:30 p.m. to 5 p.m., will be devoted to Parkinson’s disease.

This website will be updated as registration and additional meeting information become available.


September 22, 2015


9:00 a.m. to 5:00 p.m.


FDA White Oak Campus
10903 New Hampshire Ave.
Bldg. 31 Conference Center (the Great Room)
Silver Spring, MD 20993-0002


To register for this meeting, visit: Register onlinedisclaimer icon

Registration to attend the meeting must be received by September 14, 2015.

Webcast Link

    Docket Comments


Additional Information:

    Huntington's Disease - Voice of the Patient (Public Meeting: September 22, 2015) (PDF - 385KB) 



Page Last Updated: 05/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English